Molecular Epidemiology and Diversity of SARS-CoV-2 in Ethiopia, 2020 2022

3

- Abay Sisay^{1, 2, ¶,*}, Derek Tshiabuila^{3, 4,¶} Abraham Tesfaye^{1,5}, Gerald Mboowa⁶, Samuel O. Oyola⁷,
 Sofonias Kifle Tesema⁶, Cheryl Baxter^{3,4}, Darren Martin^{3,4}, Richard Lessells^{3,4}, Houriiyah Tegally^{3,4}
- 7 Stephanie van Wyk^{3,4}, Monika Moir^{3,4}, Jennifer Giandhari ^{3,4}, Sureshnee Pillay^{3,4}, Lavanya Singh^{3,4},
- 8 Yajna Ramphal^{3,4}, Arisha Maharaj^{3,4}, Yusasha Pillay^{3,4}, Akhil Maharaj^{3,4}, Yeshnee Naidoo^{3,4},
- 9 Upasana Ramphal^{3,4}, Lucious Chabuka^{3,4}, Eduan Wilkinson^{3,4}, Tulio de Oliveira^{3,4,8}, Adey Feleke
- 10 Desta² and James E. San^{3,4,*}
- 11
- ¹Department of Medical Laboratory Sciences, College of Health Sciences, Addis Ababa University,
 Addis Ababa, Ethiopia
- ¹⁴ ²Department of Microbial, Cellular, and Molecular Biology, College of Natural and Computational
- 15 Sciences, Addis Ababa University, Addis Ababa, Ethiopia.
- ¹⁶ ³KwaZulu-Natal Research Innovation and Sequencing Platform (KRISP), Nelson R Mandela School
- 17 of Medicine, University of KwaZulu-Natal, Durban, South Africa.
- ⁴Centre for Epidemic Response and Innovation (CERI), School of Data Science and Computational
- 19 Thinking, Stellenbosch University, Stellenbosch, South Africa.
- ⁵Diagnostic Unit, Center for Innovative Drug Development and Therapeutic Trials for Africa, CDT-
- 21 Africa, Addis Ababa, Ethiopia
- ⁶ Institute of Pathogen Genomics, Africa Center for Disease Control and Prevention (Africa CDC),
- 23 Addis Ababa, Ethiopia.
- ²⁴ ⁷International Livestock Research Institute (ILRI), Nairobi, Kenya.
- ²⁵ ⁸Department of Global Health, University of Washington; Seattle, USA.
- 26 27
- ²⁸ *Corresponding author(s): Abay Sisay (<u>abay.sisay@aau.edu.et</u>), San E James
- 29 (sanemmanueljames@gmail.com)
- 30 [¶] These authors contributed equally to this work

31 Abstract

Ethiopia is the second most populous country in Africa and the sixth most affected by 32 COVID-19 on the continent. Despite having experienced five infection waves, >499 000 33 cases, and ~7 500 COVID-19-related deaths as of January 2023, there is still no 34 detailed genomic epidemiological report on the introduction and spread of SARS-CoV-2 35 in Ethiopia. In this study, we reconstructed and elucidated the COVID-19 epidemic 36 dynamics. Specifically, we investigated the introduction, local transmission, ongoing 37 evolution, and spread of SARS-CoV-2 during the first four infection waves using 353 38 high-quality near-whole genomes sampled in Ethiopia. Our results show that whereas 39 viral introductions seeded the first wave, subsequent waves were seeded by local 40 transmission. The B.1.480 lineage emerged in the first wave and notably remained in 41 circulation even after the emergence of the Alpha variant. The B.1.480 was out-42 competed by the Delta variant. Notably, Ethiopia's lack of local sequencing capacity was 43 further limited by sporadic, uneven, and insufficient sampling that limited the 44 incorporation of genomic epidemiology in the epidemic public health response in 45 Ethiopia. These results highlight Ethiopia's role in SARS-CoV-2 dissemination and the 46 urgent need for balanced, near-real-time genomic sequencing. 47

48

49 Keywords: COVID-19, Molecular epidemiology, SARS-CoV-2, Whole Genome Sequence, Ethiopia

50 Introduction

51 Ethiopia is a landlocked country in Eastern Africa [1, 2]. It is further one of the most populous countries on the continent, and following the global trend, has accordingly 52 53 endured severe economic and healthcare burdens due to the ongoing COVID-19 pandemic [3,4]. On 13 March 2020, the Federal Ministry of Health in Ethiopia reported 54 55 its first COVID-19 case in Addis Ababa. By February 2022, Ethiopia had recorded approximately 494,760 confirmed cases and 7,572 deaths [5, 6]. Despite various 56 57 pandemic mitigation strategies implemented by the government (Table S1), the number of COVID-19 cases continued to rise. Ethiopia currently constitutes one of the 58 most severely affected countries on the African continent. On the 8th of April 2020. the 59 Ethiopian government declared a 5-month national state of emergency to control and 60 contain the growth rate of the local epidemic and support mitigation mechanisms [7,8]. 61 These emergency measures included the closing of schools and other academic 62 institutes, restrictions on large gatherings, and implementation of mask mandates. 63 These restrictions were complemented by encouraging social distancing and hand 64 washing using multimedia campaigns [7, 9, 10]. While genetic diversity is a major 65 driver of epidemic dynamics, until now, no detailed molecular epidemiology and 66 genetic diversity analyses of SARS-CoV-2 have been performed in Ethiopia. To 67 address this problem, we analyzed 353 high-quality near complete SARS-CoV-2 68 genomes sampled in Ethiopia against a globally representative set to characterize the 69 70 introduction, transmission, and spread of SARS-CoV-2 in Ethiopia.

71 Materials and Methods

72 **Ethical Consideration**

This study was reviewed and got approved by Addis Ababa University, College of
Health Science Institutional Review Board (IRB) (IRB # 029/20/Lab), IRB of the
Department of Medical Laboratory Sciences, Addis Ababa University (reference #MLS/174/21), IRB office of Addis Ababa City Administration Health Bureau,
AAPHREML (Reference #- AAHB/4039/227) and also from Addis Ababa University,
College of Natural and Computational Science IRB (IRB #- CNCSDO/604/13/2021),
by Yekatit 12 Hospital Medical College (IRB protocol # 75/20) and also reviewed and

approved by the Federal Democratic Republic of Ethiopia National Ethics Committee
at the Ministry of Science and Higher Education (MoSHE) (IRB #021/246/820/21).

82 Study Design, Period, and Setting

We leveraged samples collected from confirmed Ethiopian SARS-CoV-2 cases 83 recorded between July 2020 and February 2022 to produce whole and near-whole 84 genomes. Specifically, whole genome sequencing (WGS) was carried out on a subset 85 of RT-PCR positive samples (N=353) collected during the first four waves of the 86 87 pandemic in Ethiopia. The genomes can be further classified according to the sampling strategy, i.e., community surveillance (n=170), contacts of confirmed cases 88 (n=78), and suspected cases (symptomatic but yet to be confirmed by laboratory 89 results) (n=105), (Figure S2). Nasopharyngeal (NP) swab specimens were collected 90 91 using 2ml of Viral Transport Medium (VTM), (China, Miraclean Technology Co., Ltd., www.mantacc.com) from patients in Addis Ababa, Amhara, Oromia, and the Southern 92 Nations, Nationalities, and Peoples Regional States (provinces) of the country. The 93 94 number of samples selected from each region was based on the epidemic distribution of the diseases across the country (Figure S3). These areas are known to have high 95 96 population densities and cover almost three-quarters of the country's inhabitants [11, 12]. Only samples with cycle threshold (Ct) values under 30 were considered viable 97 98 and submitted for sequencing

99 Quality Assurance

We implemented a comprehensive total quality management system to ensure the quality of our sequence data throughout the process (from pre-analytical to postanalytical). The specimens with RT-PCR Ct values <30 were stored in a -80°C freezer at Arsho Advance Medical Laboratories Plc: an ISO 15189 accredited laboratory [13].

104 **RNA Extraction and Viral Detection**

Extraction, purification, and viral detection using RT-PCR were done as per our previous work and respective manufacturer recommendations [14-17]. Viral detection was done at the Ethiopian Public Health Institute (EPHI), AAPHREM center laboratory, Yekatit 12 Hospital, Arsho medical laboratory, and Addis Ababa University.

These were amongst the established RT-PCR laboratories where the majority of COVID-19 testing was performed. SARS-CoV-2 positive samples from the first three waves of the pandemic were shipped to CERI/KRISP (South Africa), and from the fourth wave (103) to ILRI (Kenya) for whole genome sequencing. All biological specimens were transported following a triple packaging biosafety and biosecurity protocol.

115 Next-Generation Sequencing of SARS-CoV-2

116 WGS was performed using either the Illumina or the Oxford Nanopore Technology 117 (ONT) sequencing platforms. Briefly, RNA was extracted on the automated Chemagic 118 360 system (Perkin Elmer) as per the manufacturer's instructions. Samples were lysed using proteinase K and bound using silica magnetic beads. Beads were then washed 119 and the RNA was eluted and stored at -80 °C until use. SuperScript IV reverse 120 transcriptase (Life Technologies) was then used, in combination with random hexamer 121 122 primers, to convert extracted RNA to complementary DNA. Gene-specific multiplex PCR using the ARCTIC protocol was then performed. PCR was used to generate 400 123 base pair (bp) amplicons, with an overlap of 70 bp to cover the 30 kilobases (kb) 124 SARS-CoV-2 genome. PCR products were purified using AmpureXP purification 125 beads (Beckman Coulter, High Wycombe, UK), and quantification was performed 126 using the Qubit double-strand DNA (dsDNA) High Sensitivity Assay Kit on a Qubit 4.0 127 128 instrument (Life Technologies). These libraries were then used for Illumina MiSeg and ONT GridION sequencing. 129

130 Illumina MiSeq indexed paired-end libraries were prepared using the Nextera DNA Flex Library Prep Kits (Illumina) as per the manufacturer's instructions. Tagmented 131 amplicons were barcoded with a unique barcode using the Nextera CD Indexes 132 (Illumina), which allows for library pooling. Prior to pooling, libraries were normalized 133 134 to 4 nM and pooled, then denatured using sodium acetate. Pooled libraries were then diluted and spiked with 1 % PhiX Control v3 and sequenced using a 500-cycle v2 135 MiSeq Reagent Kit on the Illumina MiSeq instrument (Illumina, San Diego, CA, USA) 136 [18. ONT Native Barcoding Expansion kits were used for ONT GridION sequencing 137 138 according to the manufacturer's protocol. Samples were multiplexed on the FLO-

139 MIN106 flowcells and ran on the GridION X5. The MinKNOW software was used to 140 monitor sequencing performance in real-time [19].

141

142 Metadata Management

143 Clinical and demographic metadata were collected from the confirmed cases using a 144 structured assessment tool by trained healthcare professionals at the triage of the 145 health facilities and from the community. A medical record number (MRN) was 146 assigned to each patient as a unique anonymous identifier as their names were not 147 linked to the MRNs submitted to sequence repositories such as GISAID, 148 EPI_SET_221214bg doi: 10.55876/gis8.221214bg.

149 Sequence Alignment, Assembly, and Phylogenetic Analysis

Fastq sequences were assembled using Genome Detective 1.133 (http://www. 150 151 genomedetective.com) [20] and the Coronavirus tool [21]. The initial assemblies 152 obtained from Genome Detective were visualized and manually edited using Geneious Prime version 2022.2.2 [22,23] to remove low-quality mutations. Nextclade was used 153 to determine the quality control profiles of the sequences. The quality metrics used for 154 the sequences in this study included genome coverage greater than 80%, ensured the 155 156 removal of unknown frameshifts, stop codon, and clustered mutations. Additionally, 157 submissions with exceedingly high and missing data (N) <3000Ns) were excluded 158 from downstream analyses. Nextclade was further employed to assign clades and lineage classifications to the sequences [24,25]. Sequences that met these quality 159 160 control thresholds were deposited in the GISAID (https://www.gisaid.org/) database, EPI_SET_221214bg doi: 10.55876/gis8.221214bg]. 161

To present a comprehensive analysis of the genomic epidemiology of SARS-CoV-2 in Ethiopia, the genomes generated in this study were combined with a globally representative set of genomes (n= 13589) that were sampled during the same period. All samples from the bordering countries to Ethiopia were included in the analysis to better model the relationship between Ethiopia and its Neighbors and infer crossborder transmission. This did not cause a sampling bias as these countries were

already characterized by a low number of sequences. Additionally, all global
sequences belonging to the B.1.480 lineage which was predominant in Ethiopia and
remained in circulation across the first three waves were included. Together, this
resulted in a dataset of 13,942 genomes. Acknowledgment was given to the
sequencing laboratories that contributed to the analysis set (EPI_SET_221214bg,
DOI: 10.55876/gis8.221214bg).

Sequences were aligned using NextAlign [26] to obtain a good codon alignment of the 174 sequences. A maximum likelihood tree topology was inferred from the resulting 175 alignment in IQTREE 2 [27] using the General Time Reversible model of nucleotide 176 177 substitution [28] The inferred phylogeny was used along with the associated metadata 178 that was obtained from GISAID, to map discrete geographical locations to each of the tips and infer locations for the internal nodes. This was done using the Mugration 179 180 package extension of TreeTime [29]. A custom Python script was then used to count the number of discrete changes occurring as we transcended the topology from the 181 182 root towards the tips. In essence, this provided a crude estimate of the number and timing of viral exchanges (import-export) between Ethiopia and the rest of the world. 183

184 Data Analysis and Visualization

The data were analyzed and visualized using R version 4.2.0 using available packages and custom scripts. The tree was visualized using the R package ggtree version 3.0.4[30].

188

189

190

192 **Results**

193

Socio-demographic Characteristics of the Study Participants along with SARS CoV-2 Variants of Concerns (VOCs)

A total of 1300 nasopharyngeal swabs were collected from four provinces in the 196 country. These samples included 181 (51.3%) specimens obtained from female 197 198 patients while 172 (48.7%) were sampled from male patients. The patient ages ranged between 2 and 86 years old, although most of the cases were between 21- and 30-199 year-old patients, with an overall estimated median age of 31.45 (IQR=26-46) years. 200 201 More than 77 % of the patients presented with mild cases (Table 1). Of these, we 202 discarded 300 due to their high CT values (i.e., > 30). The remaining 1000 samples 203 were subjected to the library preparation and 808 yielded sufficient RNA for WGS 204 following RT-PCR amplification. The WGS resulted in 353 SARS-CoV-2 sequences 205 that passed bioinformatics quality controls. (i.e., with genome coverage greater than 80%, a limited number of private mutations, no clustered mutations, and no misplaced 206 stop codons). Figure S2 illustrates a detailed breakdown of the sample processing. 207 208 During the study period, a combination of genetically distinct SARS-CoV-2 lineages were identified. The majority of these assemblies (91.7%) were classified as variants 209 of concern (VOC). 210

211 Local Epidemic Dynamics

To illuminate the local epidemic dynamics in Ethiopia, we performed an in-depth study 212 of the 353 high-quality SARS-CoV-2 genomes (Figure 1). The study period 213 214 corresponds with the first four COVID-19 waves experienced in the country. The first wave occurred between August and September 2020, the second between February 215 and March 2021, and the third occurred between July and October 2021. Each wave 216 217 was characterized by higher rates of transmission and fatality than previous waves 218 (Figure 1A). Notably, the third wave was more severe and lasted longer than the two 219 previous waves. The fourth wave began with an uptick in cases in December 2021 220 and continued to February 2022. The wave was characterized by the highest rates of

community transmission yet observed (Figure 1A). However, compared to the global
 trend at the time, it resulted in fewer deaths.

223 Across the four waves, the peak number of new cases remained relatively consistent 224 with the first and third waves reflecting a 7-day rolling average of approximately 1500 individuals. The second wave had a slightly higher 7-day rolling average of 2000 225 individuals whilst the fourth had the highest at over 4000 individuals (Figure 1A). The 226 number of new deaths across each wave had a similar trend to the average number of 227 228 new cases with the second and third waves having the highest number of new deaths 229 at approximately 50 individuals per day (Figure 1B). Vaccine rollout commenced in 230 April 2021 in Ethiopia and by February 2022, approximately 25% of the population had received at least one dose of Oxford-AstraZeneca or Sinopharm COVID-19 vaccines 231 232 (Figure 1B).

233 Phylogenetic reconstruction and Variant Detection in Ethiopia

234 Ancestral state reconstruction showed that viral imports into Ethiopia occurred 235 between August 2020 and January 2021, with the majority of importation events occurring in August 2020 [n=123], December 2020 [n=130], and January 2021 [n=169] 236 237 (Figure 1C). In comparison, September and November 2020 corresponded with the highest numbers of inferred SARS-CoV-2 exports from Ethiopia (n=109 and n =137, 238 respectively; Figure 1D, Figure S4). The majority of inferred importation events were 239 from Eastern Africa [n=324] origins, whereas most of the inferred exportation events 240 241 were generally attributed to Western European and Asian origins (n=20 and n=141 242 respectively). Overall, we identified 570 importation and 446 exportation events during the study period. 243

Our early sequences sampled between November and December 2020 represented 244 two lineages, B.1/B.1.1 and B.1.480, with most of the sequences classified as 245 246 B.1/B.1.1. These two lineages continued to circulate throughout the first quarter of 2021 (January to March). The B.1.480 lineage was thought to have originated in 247 Ethiopia. In our study, 21 genome assemblies were assigned to this emerging lineage. 248 10.55876/gis8.230126dv). (EPI_SET_230126dy, 249 doi: Phylogenetic inference

250 supported that this lineage was a monophyletic clade. Despite its persistence in 251 Ethiopian populations for an extended period, this variant did not disseminate globally 252 as was observed for other VOC and ultimately only constituted only 473 GISAID submissions during the progression of the pandemic, EPI_SET_230126vf, doi: 253 254 10.55876/gis8.230126vf. Nevertheless, according to GISAID submissions, this lineage was detected in neighboring countries such as Kenya, Somalia, Djibouti, and Guinea-255 256 Bissau. This lineage was further disseminated internationally where it was detected in Australia, the United States of America, Canada, Japan, Israel, Hong Kong, and South 257 Korea. This period was followed by the detection and rise to dominance of VOCs in 258 259 the country.

260 In January 2021, the first case of the Alpha variant was detected. Within a span of one month, it had reached equal prevalence to B.1/B.1.1. The B.1.1 continued to 261 262 circulate in low prevalence with the cases detected until May 2021. Alpha was however short-lived as the Delta variant emerged. The Delta variant was first detected 263 264 in February 2021. Thereafter, it quickly outcompeted all other lineages (Figure S5). By April, it had become the most prevalent variant. The predominant Delta variant sub 265 266 lineages where AY.120 (116 sequences, 46.4%) and B.1.617.2 (50 sequences, 20%). The Delta variant seeded the 3rd wave in Ethiopia. Although no sequence data was 267 268 available from September to December 2021, the majority of the cases sampled and sequenced from January 2022 were attributed to the Omicron lineage (Fig 1A & 2A). 269 270 Over the course of the study period, we identified 37 distinct lineages in circulation 271 (Fig 2 A, Fig 2B, Figure S6).

The phylogenetic reconstruction revealed close relatedness (not substantially 272 observed levels of divergence) among sequences assigned to the same lineages. 273 274 However, this observation did not hold for samples assigned to the Delta variant 275 (Figure 2C). Sequences attributed to the Delta variant showed greater variation in 276 sequence composition. Moreover, higher levels of phylogenetic clusters, associated 277 with community transmission, were observed during the study period. Phylogenetic clusters and associated community transmission events were also observed for the 278 279 Omicron lineage (Figure 2C).

280

281 Discussion

In this study, we investigated the introduction of SARS-CoV-2 viral lineages, local 282 283 transmission, and its evolution within Ethiopia. This study represents the first of its 284 kind as no other molecular epidemiology investigation has been conducted for this country and provided an overview of the pandemic progression relative to a global 285 context. Our results show that SARS-CoV-2 was introduced into Ethiopia on multiple 286 287 occasions, with most introductions originating from Eastern African countries. These 288 introductions included 37 distinct SARS-CoV-2 lineages and four VOCs, namely Alpha, Beta, Delta, and Omicron lineages. Of the introduced lineages the B1.480 289 persisted and remained in circulation from December 2020 to August of 2021. 290

Our findings show that as of February 2022, Ethiopia had experienced four distinct 291 COVID-19 waves. Although various preventive strategies such as the mandatory 292 293 wearing of masks, and media awareness campaigns were adopted together with a 294 mandatory 14-day self-quarantine regulation for all international travelers arriving in the country [5], Ethiopia remained vulnerable to SARS-CoV-2 introductions. Our 295 296 results showed that despite preventative measures viral introduction events continued 297 to occur and were followed by community transmission. This in turn facilitated a continued increase in case numbers. This could be attributed to the partial restriction 298 of public transport which is an import mode of SARS-CoV-2 transmission [5, 31]. 299 300 During lockdowns, the operation of economic activities did not cease as they were deemed necessary to support the already fragile economic and socioeconomic 301 situation of the country. This made lockdowns ineffective in preventing local 302 transmission and epidemic growth. By 30 April 2021, the total number of cases and 303 deaths had surpassed 257442 and 3688, respectively [1, 3], and has currently 304 305 increased to >499000 and 7500 deaths.

Our findings show that Ethiopia experienced poor sampling mostly limited to Addis Ababa. Temporal sampling was also hampered by periods of limited sampling and, lack of local sequencing capacity resulting in substantial delays that in turn may cause

309 the degradation of samples during transit. Yet, an in-depth understanding of the 310 COVID-19 pandemic progression in Ethiopia remains of paramount importance to aid 311 the navigation of ongoing and future pandemics within these regions [32]. Indeed, 312 Ethiopia has had several viral outbreaks in recent history, in addition to the ongoing COVID-19 pandemic. Some of the notable outbreaks include Measles, and mosquito-313 314 borne illnesses such as Yellow fever, Chikungunya, and Malaria [32, 33]. Thus, scaling up of local and regional pathogen genomic sequencing capacity and a robust 315 316 pathogen genomic surveillance infrastructure is thus required to shorten the turnaround time and to allow for early public health response [34]. Additionally, during 317 the onset of the pandemic, a survey on outbreak readiness highlighted a dire need for 318 not only pathogen surveillance in Ethiopia but Ethiopia further scored only 52% on the 319 320 Ready Score index, which shows that the nation still has progress to be made to increase case tracing and identification, increase healthcare and testing facilities, 321 provide clear operational guidelines on preventive measures across various 322 323 organizations, businesses, and community settings, as well as proactive steps to 324 maintain life during social and economic lockdowns[3, 35]. Ethiopia, as with many other African countries, has limited resources to deal with these outbreaks, and often 325 326 depends on international aid to help control and prevent these diseases [10, 36, 37].

Over the course of four waves, we estimated 570 introductions and 446 exportation 327 events occurred. This is consistent with the relatively small number of lineages 328 329 identified during the study period, although could also be attributed to under and 330 sparse sampling that likely omitted lineages circulating at low prevalence. The short generation time associated with RNA viruses could also imply that viruses circulating 331 during the period preceding the emergence of Omicron that became extinct would not 332 have been detected. The phylogenetic inference and that of the geographical 333 distribution of the Ethiopian-emerging B.1.480 lineage suggest that Ethiopia serves as 334 a source for viral introductions not only to neighboring countries but also further 335 336 abroad. Ethiopia serves as a travel hub for this African region connecting this region in Africa to neighboring countries and further abroad. Possible disease dissemination 337 338 was most likely a result of travel to and from Ethiopia via air, land, and waterways [37, 339 38]. Ethiopia is strategically located on the Red Sea, making it an important transit

point for goods moving between Africa, the Middle East, and Asia. The main international airport in Ethiopia is Addis Ababa Bole International Airport facilitates high travel volumes which most likely contributed to viral amplification in the country followed by Ethiopian-originating viral exportation events. It is therefore imperative to have concerted, collaborative action to achieve pandemic mitigation.

345 We observed a reduction in the number of new deaths reported during the fourth wave. This is consistent with the immunity acquired protection from a large number of 346 infections from the preceding waves and increases in the total number of vaccinated 347 individuals. A seroprevalence study among health care workers revealed a 348 349 seropositivity rate of 39.6% [39] while another study the estimated the prevalence rate 350 at over 50% [40]. However, only about 0.4% of the population has reportedly been 351 infected with COVID-19: much fewer than the estimated seroprevalence rates estimated for the population. Therefore, taken together these statistics suggest that 352 case numbers may remain widely underreported. Reduced testing further hinders 353 354 effective genome surveillance as fewer samples were available to be subjected to 355 whole genome analyses and influences the accuracy of epidemiological conclusions 356 drawn.

In comparison to other countries, Ethiopia has very low vaccination coverage. As of 357 December 2021, at least 1 000 000 Ethiopians had been vaccinated. It is important to 358 note that COVID-19 vaccines in Ethiopia were prioritized based on criteria such as 359 occupation, age, medical condition, people that work in aggregate settings, the elderly, 360 and people with comorbidities known to increase the risk of adverse COVID-19 361 362 outcomes^[41]. Moreover, priority was given to those deemed as frontline medical staff, followed by non-frontline medical staff. This strategy was effective in slowing the 363 364 evolutionary rate of the virus as SARS-CoV-2 is prone to evolution in 365 immunosuppressed individuals experiencing chronic infection [42-44]. Vaccination has 366 also been shown to decrease the overall SARS-CoV-2 infection rate from 9.0% (95%) Crl: 8.4% - 9.4%) without vaccination to 4.6% (95% Crl: 4.3% - 5.0%) with the 367 368 highest relative reduction noted among individuals aged 65 and above. Adverse

outcomes, such as deaths, are reduced by approximately 69.3% (95% Crl: 65.5%73.1%) with lowered vaccination coverage [45].

371 Analysis of genomes and lineages across the study period highlighted the changes in 372 the population dynamics of the viral lineages circulating in Ethiopia. The B.1 and B.1.1 lineages dominated the first wave, persisted throughout the next two waves, and were 373 characterized by the well-known D614G mutation [46]. This mutation has been linked 374 to increased viral replication and transmissibility [38, 46]. Subsequent waves were 375 376 dominated by the VOCs Alpha, Beta, Delta, and Omicron. These VOCs evolved to evade overcome host immunity from infection with ancestral viruses and vaccination. 377 378 By doing so these newly emerging variants fueled renewed infectious waves and were often associated with increased transmissibility compared to their 379 genetic 380 predecessors [47-49]. The Omicron variant (specifically, lineage BA.1.1) had a reproduction number four times higher than Delta. It is considered the fifth variant of 381 concern first detected in November/December 2021 [50-53]. 382

One important lineage in the context of Ethiopia was the B.1.480, a distinct B lineage, 383 which emerged during the second wave. This variant was responsible for 2.77% of the 384 385 sampled cases. Notably, this variant was previously detected in passengers originating from not only Ethiopia but also with those originating from European 386 countries such as the United Kingdom and France, as well as from travelers from 387 United Arab Emeritus [50-53]). Unlike other VOCs, this lineage did not reach global 388 transmission and has only 473 submissions to the GISAID platform, however, it did 389 persist in Ethiopian populations for extended periods of time. Other worrisome 390 391 mutations carried by this lineage included the Spike mutation M1229I and D614G [46,47,49,54]. 392

In conclusion, the changing nature of the pandemic over time in Ethiopia has been driven by lineage turnovers that, while dominated by VOCs and B.1.480, include other lineages (A, B.1, B.1.1). Results from this study, and that of others (ref listed above), showed that despite pandemic mitigation strategies implemented by the country, Ethiopia remained vulnerable to viral introduction events and served as a source of

viral introductions internationally. The COVID-19 pandemic is still ongoing and the 398 evolution of the virus is continuing to yield new variants some of which will likely reflect 399 400 altered viral behavior such as increased transmissibility, immune evasiveness, or altered pathogenicity. It is therefore crucial that ongoing genomic surveillance be 401 402 strengthened and conducted to present real-time data generation to determine the geographic distribution of these variants and enable the implementation of appropriate 403 404 disease mitigation strategies.

405 Acronyms /abbreviations

AAPHREML	Addis Ababa public health research and emergency management					
	laboratory					
AAU	Addis Ababa University					
ACDC	Africa center for disease prevention and control					
CERI	Centre for Epidemic Response and Innovation					
CI	Confidence Interval					
СТ	Cycle Threshold					
GISAID	Global Initiative on Sharing All Influenza Data					
KRISP	KwaZulu-Natal Research Innovation and Sequencing Platform					
NAAT	Nucleic Acid Amplification Tests					
PCR	Polymerase Chain Reaction					
RNA	Ribose Nucleic Acid					
RT-PCR	Reverse Transcriptase Polymerase Chain Reaction					
SARS-CoV-2	severe acute respiratory syndrome novel corona virus-2					
VOCs	Variants of Concern					
VTM	Virus Transport Medium					
WHO	World Health Organization					
SDG	sustainable development goal					
COVID-19	Coronavirus disease 2019					

406

407 Funding

This research was financed by Addis Ababa University through the COVID-19-AAU research fund for staff with a reference #- PR/5.15/590/12/20 and adaptive research and problem-solving projects with Ref # AR/043/2021 and RD/PY-148/2021. Also, this work was realized by the generous financial and technical support of the AU through Africa CDC, PGI. No more external funding was received. The APC was funded by Africa Pathogen Genomics Initiative (Africa PGI).

The funders had no role in the study design, data collection, analysis, decision to publish, or preparation of the manuscript. The contents are purely the responsibilities of the authors and did not represent and reflect the view of the founder.

417 Author Contributions

418 AS and AFD conceived and designed the experiments; AS, DT and SEJ performed 419 the data analysis and experiments; AS, DT, AFD and SEJ analyzed the data; GM, SO,

- 420 SKT, CB, DM, RL, HT, MM, SvW, EW, TDO contributed materials/analysis tools; AT,
- 421 AFD and SEM supervise the work; AS, DT, SvW and SEJ wrote the paper. All
- 422 authors read the final version of the manuscript.

423 Informed Consent Statement

424 All participants gave written informed consent for participation and publication.

425 **Declaration of Competing Interest**

We all the authors declare that we have no known competing interests or personal relationships that could have appeared to influence the work reported in this research paper.

429 Data availability

All the generated sequences used for this manuscript have been deposited in the GISAID sequence database and are purely publicly available. However, it's subject to the terms and conditions of the GISAID database, <u>https://www.gisaid.org/</u>, GISAID Identifier: EPI_SET_221214bg, DOI: <u>10.55876/gis8.221214bg</u>.

434 Acknowledgment

We would like to acknowledge Addis Ababa University for giving us the opportunity and financing the research. This work is realized with the generous financial and technical support of Africa CDC, PGI

- 438 We are very grateful and acknowledge the CERI and KRISP (South Africa) & ILRI 439 (Kenya) for supporting this work by performing the whole genomic sequencing.
- We also wish to extend our gratitude to Arsho Medical Laboratories for supporting this
 research by giving us a -80 ^{Oc} refrigerator for centrally storing our specimens.
- Last but not least we are very glad and thankful to Retina Pharmaceutical for supporting this work by availing required pharmaceutical inquiries.
- 444
- 445
- 446

447

448 **Reference**

1. Ethiopia: the World 449 Bank.https://www.worldbank.org/en/country/ethiopia/overview . Accessed on 25 450 Jan 2023. 451 Ebssa Wakwaya. "The promise of regional projects for Africaâ€[™]s landlocked 452 countries: Focusing on Ethiopia." African Journal of Political Science and 453 International Relations 9.2 (2015): 67-75 454 3. Zhang W, Persoz L, Hakiza S, Biru L, Girmatsion L. Impact of COVID-19 on 455 456 Food Security in Ethiopia. Epidemiologia. 2022; 3(2):161-178. https://doi.org/10.3390/epidemiologia3020013 457 4. https://www.un.org/ohrlls/sites/www.un.org.ohrlls/files/impact of covid19 and 458 responses_in_lldcs.pdf 459 5. University JH. Johns Hopkins University JH. worldometers COVID-19 Daily 460 461 update 2022 [Available from: https://www.worldometers.info/coronavirus/. 6. World Health Organization (WHO Africa). First case of COVID-19 confirmed in 462 463 Ethiopia. https://www.afro.who.int/news/first-case-covid-19-confirmedethiopia#:~:text=March%2013%2C%2020%2C%20The%20Federal,in%20C 464 465 hina%20in%20December%202019. 7. Lanyero B, Edea ZA, Musa EO, Watare SH, Mandalia ML, Livinus MC, et al. 466 467 Readiness and early response to COVID-19: achievements, challenges, and lessons learnt in Ethiopia. BMJ global health. 2021; 6(6). 468 469 8. Ethiopian Public Health Institute, EPHI. COVID-19 PANDEMIC PREPAREDNESS AND RESPONSE IN ETHIOPIA WEEKLY BULLETIN Nov 470 2021 [updated 2022. Available from: https://ephi.gov.et/download/pheoc/. 471 9. WHO. COVID-19 Preparedness Bulletin Ethiopia 2020 [Available from: 472 https://extranet.who.int/sph/covid-19-preparedness-bulletin-ethiopia. 473 474 10. Amhare AF, Tao Y, Li R, Zhang L. Early and Subsequent Epidemic Characteristics of COVID-19 and Their Impact on the Epidemic Size in 475

476 Ethiopia. *Front Public Health*. 2022;10: 834592. Published 2022 May 11.
477 doi:10.3389/fpubh.2022.834592

- 11. Leulseged TW, Abebe KG, Hassen IS, et al. COVID-19 disease severity and
 associated factors among Ethiopian patients: A study of the millennium COVID19 care center. *PLoS One.* 2022;17(1):e0262896. Published 2022 Jan 27.
- 481 doi:10.1371/journal.pone.0262896
- 12. Abdella S, Riou S, Tessema M, et al. Prevalence of SARS-CoV-2 in urban and
 rural Ethiopia: Randomized household serosurveys reveal level of spread
 during the first wave of the pandemic. *EClinicalMedicine*. 2021; 35:100880.
 Published 2021 May 7. doi:10.1016/j.eclinm.2021.100880
- 486 13. Edgar RC. MUSCLE: multiple sequence alignment with high accuracy and high
 487 throughput. Nucleic acids research. 2004;32(5):1792-7.
- 14. Sisay A, Abera A, Dufera B, Endrias T, Tasew G, Tesfaye A, et al. Diagnostic
 accuracy of three commercially available one step RT-PCR assays for the
 detection of SARS-CoV-2 in resource limited settings. PloS one. 2022;
 17(1):e0262178.
- 492 15.MOLBIOL T. RT-PCR test kits and VirSNiP Mutation Assays for strain
 493 surveillance [Available from: <u>https://www.tib-molbiol.de/covid-19</u>.
- 494 16. World Health Organization W. Emergency Use Listing Procedure for in vitro
 495 diagnostics 2020 [Available from: <u>https://www.who.int/teams/regulation-</u>
 496 <u>prequalification/eul/in-vitro-emergency-use-listing-procedure</u>.
- 497 17.BGI. Real-Time Fluorescent RT-PCR Kit for Detecting SARS-CoV-2 2020
 498 [Available from: <u>https://www.bgi.com/us/sars-cov-2-real-time-fluorescent-rt-pcr-</u>
 499 <u>kit-ivd/</u>
- 18. Tshiabuila D, Giandhari J, Pillay S, et al. Comparison of SARS-CoV-2
 sequencing using the ONT GridION and the Illumina MiSeq. *BMC Genomics*.
 2022; 23(1):319. Published 2022 Apr 22. doi:10.1186/s12864-022-08541-5
- 19. Pembaur A, Sallard E, Weil PP, Ortelt J, Ahmad-Nejad P, Postberg J.
 Simplified Point-of-Care Full SARS-CoV-2 Genome Sequencing Using
 Nanopore Technology. Microorganisms. 2021; 9(12).

20. Vilsker M, Moosa Y, Nooij S, et al. Genome Detective: an automated system for
 virus identification from high-throughput sequencing data. *Bioinformatics*.
 2019;35(5):871-873. doi:10.1093/bioinformatics/bty695

- 21. Cleemput S, Dumon W, Fonseca V, et al. Genome Detective Coronavirus
 Typing Tool for rapid identification and characterization of novel coronavirus
 genomes. *Bioinformatics*. 2020;36(11):3552-3555.
- 512 doi:10.1093/bioinformatics/btaa145
- 22. Larsson A. AliView: a fast and lightweight alignment viewer and editor for large
 datasets. Bioinformatics (Oxford, England). 2014; 30(22):3276-8.
- 23. Edgar RC. MUSCLE: multiple sequence alignment with high accuracy and high
 throughput. Nucleic acids research. 2004; 32(5):1792-7.
- 517 24. Shu Y, McCauley J. GISAID: Global initiative on sharing all influenza data 518 from vision to reality. Euro surveillance: bulletin Europeen sur les maladies
 519 transmissibles = European communicable disease bulletin. 2017;22(13).
- 520 25. Nextclade. Next clade. <u>https://clades.nextstrain.org/</u> 2021 [Available from: 521 <u>https://clades.nextstrain.org/</u>.
- 52226.Aksamentov I., Neher R. Nextalign: Viral Genome Reference Alignment.523[(accessed on 16 Jan 2023]. Available524online: https://github.com/neherlab/nextalign
- 27. Minh BQ, Schmidt HA, Chernomor O, Schrempf D, Woodhams MD, von
 Haeseler A, Lanfear R. IQ-TREE 2: New Models and Efficient Methods for
 Phylogenetic Inference in the Genomic Era. Mol Biol Evol. 2020 May
 1;37(5):1530-1534. doi: 10.1093/molbev/msaa015.
- 529 28. Gatto L, Catanzaro D, Milinkovitch MC. Assessing the applicability of the GTR
 530 nucleotide substitution model through simulations. *Evol Bioinform Online*.
 531 2007;2:145-155. Published 2007 Feb 4.
- 29. Pavel Sagulenko, Vadim Puller, Richard A Neher, TreeTime: Maximumlikelihood phylodynamic analysis, *Virus Evolution*, Volume 4, Issue 1, January
 2018, vex042, <u>https://doi.org/10.1093/ve/vex042</u>

535 30. Yu G, Smith DK, Zhu H, Guan Y, Lam TT-Y. ggtree: an r package for 536 visualization and annotation of phylogenetic trees with their covariates and 537 other associated data. Methods in Ecology and Evolution. 2017;8(1):28-36. 31. Ellingjord-Dale, M., Kalleberg, K.T., Istre, M.S. et al. The use of public transport 538 and contraction of SARS-CoV-2 in a large prospective cohort in Norway. BMC 539 540 Infect Dis 22, 252 (2022). https://doi.org/10.1186/s12879-022-07233-5 32. Mekuriaw W, Kinde S, Kindu B, Mulualem Y, Hailu G, Gebresilassie A, et., al. 541 Epidemiological, Entomological, and Climatological Investigation of the 2019 542 Dengue Fever Outbreak in Gewane District, Afar Region, North-East 543 Ethiopia. Insects. 2022; 13(11):1066. https://doi.org/10.3390/insects13111066 544 545 33. Mengesha Tsegaye, M., Beyene, B., Ayele, W. et al. Sero-prevalence of yellow 546 fever and related Flavi viruses in Ethiopia: a public health perspective. BMC Public Health 18, 1011 (2018). https://doi.org/10.1186/s12889-018-5726-9 547 548 34. Tegally H, San JE, Cotten M, et al. The evolving SARS-CoV-2 epidemic in Africa: Insights from rapidly expanding genomic surveillance. Science. 549 2022;378(6615):eabq5358. doi:10.1126/science.abq5358 550 551 35. Abagero A, Ragazzoni L, Hubloue I, Barone-Adesi F, Lamine H, Addissie A, Della Corte F, Valente M. A Review of COVID-19 Response Challenges in 552 Ethiopia. Int. J. Environ. Res. Public Health. 2022; 19(17):11070. 553 https://doi.org/10.3390/ijerph191711070 554 555 36. Tessema GA, Kinfu Y, Dachew BA, Tesema AG, Assefa Y, Alene KA, et al. 556 The COVID-19 pandemic and healthcare systems in Africa: a scoping review of preparedness, impact and response. BMJ global health. 2021;6(12):e007179. 557 558 37. Nigussie H. The Coronavirus Intervention in Ethiopia and the Challenges for Implementation. Front. Commun., 21 May 2021 Sec. Health Communication 559 Volume 6 – 2021. https://doi.org/10.3389/fcomm.2021.562512 560 561 38. Ngeh S, Vogt F, Sikazwe CT, et al. Travel-associated SARS-CoV-2 562 transmission documented with whole genome sequencing following a long-haul international flight. J Travel Med. 2022;29(6):taac057. doi:10.1093/jtm/taac057 563

39. Gelanew T, Seyoum B, Mulu A, et al. High seroprevalence of anti-SARS-CoV-2
 antibodies among Ethiopian healthcare workers. *BMC Infect Dis*.
 2022;22(1):261. Published 2022 Mar 16. doi:10.1186/s12879-022-07247-z

- 40. Gudina EK, Ali S, Girma E, et al. Seroepidemiology and model-based
 prediction of SARS-CoV-2 in Ethiopia: longitudinal cohort study among front line hospital workers and communities. *Lancet Glob Health*. 2021;9(11):e1517 e1527. doi:10.1016/S2214-109X(21)00386-7
- 41.COVID-19 Vaccine tracker. https://www.reuters.com/graphics/world coronavirus-tracker-and-maps/vaccination-rollout-and-access/
- 42. Kemp, S.A., Collier, D.A., Datir, R.P. *et al.* SARS-CoV-2 evolution during
 treatment of chronic infection. *Nature* 592, 277–282 (2021).
 <u>https://doi.org/10.1038/s41586-021-03291-y</u>
- 43. Wilkinson SAJ, Richter A, Casey A, Osman H, Mirza JD, Stockton J, et al.
 Recurrent SARS-CoV-2 mutations in immunodeficient patients. Virus evolution.
 2022;8(2):veac050.
- 44. Weigang, S., Fuchs, J., Zimmer, G. *et al.* Within-host evolution of SARS-CoV-2
 in an immunosuppressed COVID-19 patient as a source of immune escape
 variants. *Nat Commun* 12, 6405 (2021). <u>https://doi.org/10.1038/s41467-021-</u>
 26602-3
- 583 45. Moghadas SM, Vilches TN, Zhang K, et al. The impact of vaccination on outbreaks States. Preprint. *medRxiv*. COVID-19 in the United 584 Published 2. 585 2021;2020.11.27.20240051. 2021 Jan doi:10.1101/2020.11.27.20240051 586
- 46. Korber B, Fischer WM, Gnanakaran S, et al. Tracking Changes in SARS-CoV-2
 Spike: Evidence that D614G Increases Infectivity of the COVID-19 Virus. *Cell*.
 2020;182(4):812-827.e19. doi:10.1016/j.cell.2020.06.043
- 47. Harvey, W.T., Carabelli, A.M., Jackson, B. *et al.* SARS-CoV-2 variants, spike
 mutations and immune escape. *Nat Rev Microbiol* 19, 409–424 (2021).
 <u>https://doi.org/10.1038/s41579-021-00573-0</u>
- 48. Liu Y, Rocklöv J. The reproductive number of the Delta variant of SARS-CoV-2
 is far higher compared to the ancestral SARS-CoV-2 virus. J Travel Med. 2021

595 Oct 11;28(7):taab124. doi: 10.1093/jtm/taab124. PMID: 34369565; PMCID: 596 PMC8436367.

- 49. Thakur S, Sasi S, Pillai SG, et al. SARS-CoV-2 Mutations and Their Impact on
 Diagnostics, Therapeutics and Vaccines. *Front Med (Lausanne)*. 2022;9:
 815389. Published 2022 Feb 22. doi:10.3389/fmed.2022.815389
- 50. Shrivastava S, Mhaske ST, Modak MS, Virkar RG, Pisal SS, Mishra AC, et al.
 Emergence of two distinct variants of SARS-CoV-2 and an explosive second
 wave of COVID-19: the experience of a tertiary care hospital in Pune, India.
 Archives of virology. 2022; 167(2):393-403.
- 51. Dhama K, Nainu F, Frediansyah A, Yatoo MI, Mohapatra RK, Chakraborty S, et
 al. Global emerging Omicron variant of SARS-CoV-2: Impacts, challenges and
 strategies. Journal of Infection and Public Health. 2023; 16(1):4-14.
- 52. Zhou Y, Zhi H, Teng Y. The outbreak of SARS-CoV-2 Omicron lineages,
 immune escape, and vaccine effectivity. *J Med Virol*. 2022;10.1002/jmv.28138.
 doi:10.1002/jmv.28138
- 53. Corriero A, Ribezzi M, Mele F, Angrisani C, Romaniello F, Daleno A, et., al.
 COVID-19 Variants in Critically III Patients: A Comparison of the Delta and
 Omicron Variant Profiles. *Infectious Disease Reports*. 2022; 14(3):492-500.
 https://doi.org/10.3390/idr14030052
- 54. Dubey, A., Choudhary, S., Kumar, P. *et al.* Emerging SARS-CoV-2 Variants:
 Genetic Variability and Clinical Implications. *Curr Microbiol* **79**, 20 (2022).
 https://doi.org/10.1007/s00284-021-02724-1
- 617
- 618
- 619
- 620
- 621
- 622
- 623
- 020
- 624

625 Tables, Figures and Supplementary Files

Table 1. Socio-demographic characteristics of study participants along with VOC of SARS-CoV-2 in
 Ethiopia, 2020-2022.

Variable	Class	Frequency (%)		Variant	(VOC)	
		(Alpha	Beta	Delta	Omicron
Sex	Female	181 (51.3)	10	2	99	57
	Male	172 (48.7)	7	1	102	46
Age Range	1-20	40 (11.3)	7	1	19	8
(years)	21-30	121 (34.3)	1	1	80	25
	31-40	84 (23.8)	5	1	43	30
	41-50	41 (11.6)	2	0	25	12
	51-60	21 (10.2)	2	0	18	15
	>60	31 (8.8)	0	0	16	13
Reason for	Suspect	107 (30.3)	6	1	133	2
testing	Contacts of	79 (22.4)	8	2	45	1
(during	confirmed cases					
sampling)	Community	167 (47.3)	3	0	23	100
	Surveillance					
Clinical	Asymptomatic*	53 (15)	3	0	37	5
Status of the	Mild	273 (77.3)	14	3	142	94
clients while sampling	Sever	27 (7.7)	0	0	22	4

^{628 *}Asymptomatic – a person has tested positive for COVID-19 but never exhibits any signs or symptoms of the 629 disease

630

Figure 1: SARS-CoV-2 epidemiology and variant turnover in Ethiopia: (a) 7-day rolling 631 632 average for the number of new SARS-CoV-2 cases. Others, represented in blue, comprise mostly B lineages including B, B.1, and B.1.1 lineages. The size of the dot is indicative of the 633 634 variant proportion in the population. (b) The proportion of individuals that have received at 635 least one vaccine dose in Ethiopia compared to the number of new deaths that occurred. (c) 636 Summary of the mean number of detected introductions into Ethiopia binned by month for 637 different regions across the dataset. (d) Summary of the mean number of detected 638 exportations out of Ethiopia to different regions binned by month.

639 Figure 2: SARS-CoV-2 lineage diversity in Ethiopia. (A) Proportions of SARS-CoV-2 lineages,

640 classified by Pangolin nomenclature, circulating between June 2020 and February 2022 in

- 641 Ethiopia. (B) Absolute counts of SARS-CoV-2 genomes throughout the study period. Only
- VOCs and major lineages are listed in the legend. (C) Maximum-Likelihood phylogeny of 353
- 643 SARS-CoV-2 genomes. Branches are colored by lineage.

644

645

647 List of Supplementary Files

- Table S1- Timeline of COVID-19 and major events following the first confirmed cases
- 649 in Ethiopia
- Figure S2- Consortium Diagram of Sampling for Molecular Epidemiology and Diversity
- 651 of SARS-CoV-2 in Ethiopia
- Figure S3- The sampling area covers in Ethiopia
- Figure S4-Major SARS-CoV-2 lineages of detected imported and exported Ethiopia
- 654 between June 2020 and February 2022
- Figure S5- SARS-CoV-2 Delta VOC sub tree molecular clock, Ethiopia.


656	Figure S6-Major SARS-CoV-2 lineages identified Ethiopia between June 2020 and
657	February 2022
658	
659	
660	
661	
662	
663	
664	
665	
666	
667	
668	
669	
670	
671	
672	
673	
674	
675	
676	
677	
678	
679	
680	
681	
682	
683	
684	
685	


686 Table S1 Summary of the COVID-19 timeline and major events following the first

687 confirmed cases in Ethiopia

Timeline	Major events	Remai k
December	Wuhan City, Hubei Province, China, which was reported to the WHO on 31	
2019/January	December 2019. Wuhan, China, was reported in January 2020	
2020		
27 January 2020	Prior to the WHO's declaration of a global pandemic, the federal democratic	
	republic of Ethiopia Council of Ministers 'activated' a National Public Health	
	Emergency Preparedness Centre, EOC and began preparations to deal with a	
	potential outbreak of Covid-19	
30 January 2020	the Director-General of the WHO declared COVID-19 a Public Health	-
	Emergency of International Concern	
7 February 2020	Ethiopia set up the national Influenza and Arboviruses reference laboratory as	-
	the first COVID-19 testing laboratory in the country with the support from	
	WHO and ACDC.	
March 11, 2020-	WHO declared COVID-19 as a Pandemic	
March 13, 2020,	On 12 March 2020, a week after entering the country from Burkina Faso, a	
	48-year-old Japanese national presented himself at a public health center in	
***	the capital city, Addis Ababa, and was diagnosed as having COVID-19. Since	
	Ethiopia did not have the capacity to test for COVID-19 at the onset. Thus,	
	samples were initially transported for testing to the National Institute for	
	Communicable Diseases (NICD) Laboratory in South Africa	4
15 March 2020	The second confirmed case from Ethiopian nationalities (three additional	
)cases of the COVID-19 were reported	-
20 March 2020	Anyone entering the country/international travelers/ should stay in quarantine	
	for up to 14 days at their costs	-
23 March 2020	Ethiopia closed all land borders and deployed security forces to halt the	
	movement of people along the borders (National lockdown)	-
24 March 2020	 banned all public gatherings and sports events 	
	 The closure of bars and clubs all federal employees were to work from home, except those designated 	
	by each ministry and federal agency as essential workers	
05 April 2020	The First COVID-19-related confirmed death	-
8 April 2020	A state of emergency was declared giving authorities across-the-board	-
	powers to battle the disease	
06 March 2021	The first genome sequence of SARS-CoV-2 sampled from Ethiopia was	1
*after a year of pathogen occurrence	submitted to the GISAID database	
13March, 2021	First vaccination started	

689 center during this time






716 Figure - S3a- Sampling area for Molecular Epidemiology and Diversity of SARS-CoV-2 in Ethiopia

718 Table S3b: Sequence proportion of the regional government

717

	Name of Regional	Proportion of sequencing (%)
	Addis Ababa	80%
	Oromia	8%
	Amhara	5%
	SNNPR and Sidama	5%
	Others	2%
719		
720		
721		





724

725 Figure S 4-Major SARS-CoV-2 lineages of detected imported and exported Ethiopia between June

726 2020 and February 2022

727





- 731
- 732
- 733

